Teva Pharmaceutical Industries Ltd. announced FDA approval of two products for adolescent and adult patients with asthma: AirDuo RespiClick and ArmonAir RespiClick.
Incyte and Calithera Biosciences Announce Global Collaboration to Develop and Commercialize CB-1158, a First-in-class, Small Molecule Arginase Inhibitor
Incyte Corporation and Calithera Biosciences Inc. announced that the companies have entered into a global collaboration and license agreement for the research, development and commercialization of Calithera’s first-in-class, small molecule arginase inhibitor CB-1158 in hematology and oncology.
As drug pricing continues to be a concern for the public and the new presidential administration, Merck pulled back the curtain on its U.S. pricing practices.
Billed as a measure to bolster national security, President Donald Trump’s executive order blocking travel, immigrants and refugees from seven majority-Muslim countries is having ripple effects impacting the science and biotech communities and could be the start of a brain drain in the U.S.
Novo Nordisk – the world’s top maker of diabetes drugs – is investing 115 million pounds ($145 million) in a new research center in Britain, undeterred by Brexit.
Custom- Economical and Written Dissertations on Any Matter of the Planet! Commonly inexpensive dissertation-writing providers give pupils with low quality plagiarized function which leaves a poor influence on the scores. Dissertation. While the title implies, provides probably the most affordable dissertation help to you. We never bargain on quality although although you can expect affordable […]
European prices for some off-patent cancer drugs have risen by more than 100 percent in the past five years, with two cases of hikes exceeding 1,000 percent, according to data presented at a medical conference.
The Chan Zuckerberg Initiative – founded by Priscilla Chan, a physician, and her husband, Facebook chief executive officer Mark Zuckerberg – acquired Torontobased artificial intelligence company Meta.
Amgen Receives Positive CHMP Opinion For ABP 501 (Biosimilar Adalimumab) For The Treatment Of Certain Inflammatory Diseases
Amgen announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the Marketing Authorization of ABP 501 (biosimilar adalimumab), recommending approval for all available indications.
Pfizer Receives Positive CHMP Opinion in Europe for XELJANZ (tofacitinib citrate) for the Treatment of Moderate to Severe Active Rheumatoid Arthritis
Pfizer Inc. announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency adopted a positive opinion recommending XELJANZ (tofacitinib citrate) 5 mg twice daily for the treatment of patients with moderate to severe active rheumatoid arthritis.